Home  »  Markets   »  CymaBay Therapeutics Inc. (NASDAQ:CBAY) moved down...

CymaBay Therapeutics Inc. (NASDAQ:CBAY) moved down -10.11% in a month: Spotting A Buy Candidate

CymaBay Therapeutics Inc. (NASDAQ:CBAY) shares fell to a low of $4.15 before closing at $4.18. Intraday shares traded counted 0.75 million, which was 14.26% higher than its 30-day average trading volume of 875.56K. CBAY’s previous close was $4.38 while the outstanding shares total 68.95M. The firm has a beta of 1.21. The stock’s Relative Strength Index (RSI) is 44.38, with weekly volatility at 5.25% and ATR at 0.26. The CBAY stock’s 52-week price range has touched low of $3.16 and a $9.06 high. The stock traded lower over the last trading session, losing -4.57% on 05/25/21.

Investors have identified the Biotechnology company CymaBay Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $285.74 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

CymaBay Therapeutics Inc. (CBAY) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 133.27 million total, with 7.91 million as their total liabilities.

CBAY were able to record -20.66 million as free cash flow during the 08/12/2021 quarter of the year, this saw their quarterly net cash flow reduce by 15.13 million. In cash movements, the company had a total of -20.56 million as operating cash flow.

Having a look at the company’s valuation, the company is expected to record -1.09 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on CBAY sounds very interesting.

Is the stock of CBAY attractive?

In the last 6 months, insiders have changed their ownership in shares of company stock by 0.40%.

Leave a Comment

Your email address will not be published. Required fields are marked *